Beyond breast cancer, a promising role for CDK4/6 inhibitors has also been observed in other malignancies, including NSCLC, glioblastoma (GBM), melanoma, and colorectal and ovarian cancers,39,40 which suggests their potential efficacy across multiple tumor types. Here, CDK4 is linked to ovarian cancer.